LGND Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own LGND shares is 356, representing 100.74% of the company's common stock.

AMI ASSET MANAGEMENT CORP, in the last quarter, reduced its stake in LGND by -3.96% restricting it's holding to 40.93 thousand shares of worth nearly $2.99M. GW&K INVESTMENT MANAGEMENT, LLC also lessened -28.14% of the LGND shares from its portfolio, reducing its holding to 39.77 thousand shares of worth $2.91M. PUBLIC SECTOR PENSION INVESTMENT BOARD also shunned LGND shares holding by -1.23% last quarter which brought its holding to 33.6 thousand shares worth $2.46M.

As per its latest 13F filing, STATE OF WISCONSIN INVESTMENT BOARD increased its stake in LGND by 180.48% in the last quarter. The institutional holder raised its holding to 37 thousand shares having worth more than $2.70M. SEI INVESTMENTS CO also added 224.15% more shares of LGND to its portfolio, raising its holding to 35.84 thousand shares of worth $2.62B. UBS GROUP AG also increased its LGND shares holding by 73.77% which brought its holding to 33.06 thousand shares worth $2.42M.

The insider with the most stakes in LGND is HIGGINS JOHN L , director at the company. Additionally, LGND stock is highly held by President and COO FOEHR MATTHEW W and Chief Executive Officer Davis Todd C among others.

Company executives, directors, and other insiders own 1.87% percent of Ligand Pharmaceuticals Incorporated's stock. Within the last six months, there have been 11 transaction(s) in which LGND insiders have sold stock, totaling 44.18K shares. Insiders that have sold shares include ESPINOZA OCTAVIO, LAMATTINA JOHN L, and REARDON ANDREW.

There have been 0 transaction(s) during the past 6-months in which Ligand Pharmaceuticals Incorporated insiders have bought stock, totalling 0 shares

Around 467.38K Ligand Pharmaceuticals Incorporated shares are held by insiders, which represents about 1.87% of LGND stock.

LGND director, HIGGINS JOHN L holds the largest portfolio of the company's shares. LGND shares owned by HIGGINS total nearly 422.98 thousand.

NUVEEN ASSET MANAGEMENT, LLC is the largest institutional owner in LGND which holds 43.04 thousand shares worth $3.15M or 0.25% of the total LGND shares outstanding followed by AMI ASSET MANAGEMENT CORP with ownership of 40.93 thousand shares representing 0.24% of the LGND ownership. GW&K INVESTMENT MANAGEMENT, LLC is the third largest stakeholder with 39.77 thousand shares or 0.23% of the ownership worth more than $2.91M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the LGND is concerned, it is a stock which is optionable.

Number of LGND shares short is 911.39K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 18.90M shares of LGND are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, LGND has 18.52M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for LGND is 7.07.